These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 9447497)
1. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients. Caligiuri MP; Lohr JB J Neuropsychiatry Clin Neurosci; 1997; 9(4):562-7. PubMed ID: 9447497 [TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. Caligiuri MP; Lacro JP; Jeste DV J Clin Psychopharmacol; 1999 Aug; 19(4):322-8. PubMed ID: 10440459 [TBL] [Abstract][Full Text] [Related]
3. Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication. Caligiuri MP; Rockwell E; Jeste DV Am J Geriatr Psychiatry; 1998; 6(1):75-82. PubMed ID: 9469217 [TBL] [Abstract][Full Text] [Related]
4. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344 [TBL] [Abstract][Full Text] [Related]
5. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. Honer WG; Kopala LC; Rabinowitz J J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513 [TBL] [Abstract][Full Text] [Related]
7. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics? Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894 [TBL] [Abstract][Full Text] [Related]
12. Drug-induced parkinsonism: relationship to age at onset of schizophrenia. Sandyk R; Kay SR Funct Neurol; 1991; 6(2):151-7. PubMed ID: 1680777 [TBL] [Abstract][Full Text] [Related]
13. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes. Decina P; Mukherjee S; Caracci G; Harrison K Am J Psychiatry; 1992 Aug; 149(8):1075-80. PubMed ID: 1353315 [TBL] [Abstract][Full Text] [Related]
14. Clozapine, negative symptoms, and extrapyramidal side effects. Kane JM; Safferman AZ; Pollack S; Johns C; Szymanski S; Kronig M; Lieberman JA J Clin Psychiatry; 1994 Sep; 55 Suppl B():74-7. PubMed ID: 7961579 [TBL] [Abstract][Full Text] [Related]
15. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Weiden PJ; Mann JJ; Haas G; Mattson M; Frances A Am J Psychiatry; 1987 Sep; 144(9):1148-53. PubMed ID: 2888321 [TBL] [Abstract][Full Text] [Related]
16. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. Dean CE; Kuskowski MA; Caligiuri MP J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811 [TBL] [Abstract][Full Text] [Related]
18. Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients. Cortese L; Caligiuri MP; Malla AK; Manchanda R; Takhar J; Haricharan R Schizophr Res; 2005 Jun; 75(1):65-75. PubMed ID: 15820325 [TBL] [Abstract][Full Text] [Related]
19. Higher fundamental voice frequency is related to extrapyramidal symptoms in schizophrenia. Graux J; Courtine JB; Bruneau N; Camus V; El-Hage W Schizophr Res; 2015 Feb; 161(2-3):517-8. PubMed ID: 25468179 [No Abstract] [Full Text] [Related]
20. Susceptibility to neuroleptic-induced parkinsonism--age and increased substantia nigra echogenicity as putative risk factors. Jabs BE; Bartsch AJ; Pfuhlmann B Eur Psychiatry; 2003 Jun; 18(4):177-81. PubMed ID: 12814851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]